Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment

CUB domain‐containing protein 1 (CDCP1) contributes to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance by regulating EGFR signaling pathways and is a potential target in lung cancer treatment. This study aims to identify a CDCP1 reducer that synergistically improve...

Full description

Bibliographic Details
Main Authors: Sze‐Ching Wong, Chun‐Chieh Yeh, Xun‐Yu Zhang, Chih‐Ying Hsieh, Chia‐Chien Lo, Ting‐Ting Kuo, Ching‐Chan Lin, Chih‐Hua Chao, Jing‐Pei Liu, Ling‐Chu Chang, Lu‐Hai Wang, Yuh‐Pyng Sher
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Molecular Oncology
Subjects:
8‐isopentenylnaringenin
EGFR TKI acquired resistance
lung adenocarcinoma
necrosis
synergistic effects
Online Access:https://doi.org/10.1002/1878-0261.13429

Internet

https://doi.org/10.1002/1878-0261.13429

Similar Items